Dataset Information


Immune profile of pediatric renal transplant recipients following alemtuzumab induction.

ABSTRACT: The incidence of developing circulating anti-human leukocyte antigen antibodies and the kinetics of T cell depletion and recovery among pediatric renal transplant recipients who receive alemtuzumab induction therapy are unknown. In a collaborative endeavor to minimize maintenance immunosuppression in pediatric renal transplant recipients, we enrolled 35 participants from four centers and treated them with alemtuzumab induction therapy and a steroid-free, calcineurin-inhibitor-withdrawal maintenance regimen. At 3 months after transplant, there was greater depletion of CD4(+) than CD8(+) T cells within the total, naive, memory, and effector memory subsets, although depletion of the central memory subset was similar for CD4(+) and CD8(+) cells. Although CD8(+) T cells recovered faster than CD4(+) subsets overall, they failed to return to pretransplant levels by 24 months after transplant. There was no evidence for greater recovery of either CD4(+) or CD8(+) memory cells than naïve cells. Alemtuzumab relatively spared CD4(+)CD25(+)FoxP3(+) regulatory T cells, resulting in a rise in their numbers relative to total CD4(+) cells and a ratio that remained at least at pretransplant levels throughout the study period. Seven participants (20%) developed anti-human leukocyte antigen antibodies without adversely affecting allograft function or histology on 2-year biopsies. Long-term follow-up is underway to assess the potential benefits of this regimen in children.


PROVIDER: S-EPMC3269923 | BioStudies | 2012-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6658347 | BioStudies
2012-01-01 | S-EPMC3323763 | BioStudies
2012-01-01 | S-EPMC3387484 | BioStudies
1000-01-01 | S-EPMC5170892 | BioStudies
2019-01-01 | S-EPMC6895601 | BioStudies
2015-01-01 | S-EPMC5256634 | BioStudies
2015-01-01 | S-EPMC4304935 | BioStudies
2014-01-01 | S-EPMC4231065 | BioStudies
2011-01-01 | S-EPMC3179560 | BioStudies
2018-01-01 | S-EPMC5825980 | BioStudies